Mark Cronin
Overview
Explore the profile of Mark Cronin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brockmeier E, Basili D, Herbert J, Rendal C, Boakes L, Grauslys A, et al.
Sci Total Environ
. 2022 Jul;
849:157666.
PMID: 35908689
With the large numbers of man-made chemicals produced and released in the environment, there is a need to provide assessments on their potential effects on environmental safety and human health....
2.
Ouedraogo G, Alexander-White C, Bury D, Clewell 3rd H, Cronin M, Cull T, et al.
Regul Toxicol Pharmacol
. 2022 May;
132:105161.
PMID: 35508214
Parabens are esters of para-hydroxybenzoic acid that have been used as preservatives in many types of products for decades including agrochemicals, pharmaceuticals, food and cosmetics. This illustrative case study with...
3.
Alexander-White C, Bury D, Cronin M, Dent M, Hack E, Hewitt N, et al.
Regul Toxicol Pharmacol
. 2022 Jan;
129:105094.
PMID: 34990780
This paper presents a 10-step read-across (RAX) framework for use in cases where a threshold of toxicological concern (TTC) approach to cosmetics safety assessment is not possible. RAX builds on...
4.
Bury D, Alexander-White C, Clewell 3rd H, Cronin M, Desprez B, Detroyer A, et al.
Regul Toxicol Pharmacol
. 2021 Apr;
123:104931.
PMID: 33905778
This case study on the model substance caffeine demonstrates the viability of a 10-step read-across (RAX) framework in practice. New approach methodologies (NAM), including RAX and physiologically-based kinetic (PBK) modelling...
5.
Cronin M, Doe J, Pereira M, Willett C
Regul Toxicol Pharmacol
. 2021 Mar;
122:104911.
PMID: 33662477
No abstract available.
6.
Brozek J, Canelo-Aybar C, Akl E, Bowen J, Bucher J, Chiu W, et al.
J Clin Epidemiol
. 2020 Sep;
129:138-150.
PMID: 32980429
Objectives: The objective of the study is to present the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) conceptual approach to the assessment of certainty of evidence from modeling studies...
7.
Punt A, Firman J, Boobis A, Cronin M, Gosling J, Wilks M, et al.
Toxicol Sci
. 2020 Feb;
174(2):326-340.
PMID: 32040188
Tox21 and ToxCast are high-throughput in vitro screening programs coordinated by the U.S. National Toxicology Program and the U.S. Environmental Protection Agency, respectively, with the goal of forecasting biological effects...
8.
Brockmeier E, Hodges G, Hutchinson T, Butler E, Hecker M, Tollefsen K, et al.
Toxicol Sci
. 2017 May;
158(2):252-262.
PMID: 28525648
In conjunction with the second International Environmental Omics Symposium (iEOS) conference, held at the University of Liverpool (United Kingdom) in September 2014, a workshop was held to bring together experts...
9.
Berggren E, Amcoff P, Benigni R, Blackburn K, Carney E, Cronin M, et al.
Environ Health Perspect
. 2015 May;
123(12):1232-40.
PMID: 25956009
Background: Safety assessment for repeated dose toxicity is one of the largest challenges in the process to replace animal testing. This is also one of the proof of concept ambitions...
10.
Reck F, Ehmann D, Dougherty T, Newman J, Hopkins S, Stone G, et al.
Bioorg Med Chem
. 2014 Aug;
22(19):5392-409.
PMID: 25155913
Type II bacterial topoisomerases are well validated targets for antimicrobial chemotherapy. Novel bacterial type II topoisomerase inhibitors (NBTIs) of these targets are of interest for the development of new antibacterial...